Spots Global Cancer Trial Database for pkc412
Every month we try and update this database with for pkc412 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | NCT03207334 | Acute Myeloid L... | Midostaurin Cytarabine | 18 Years - 75 Years | University of Florida | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | NCT03591510 | FLT3-mutated Ac... | Midostaurin Fludarabine Cytarabine Daunorubicin or... Mitoxantrone Etoposide | 3 Months - 17 Years | Novartis | |
| Managed Access Programs for PKC412, Midostaurin | NCT05219266 | FMS-Like Tyrosi... Acute Myeloid L... Aggressive Syst... Mast Cell Leuke... Systemic Mastoc... | midostaurin | 18 Years - | Novartis | |
| Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy | NCT02624570 | Acute Myeloid L... FLT3 Mutation, ... | Midostaurin | 18 Years - | Novartis | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | NCT03114228 | FLT3-mutated Ac... | Midostaurin | 18 Years - | Novartis | |
| PKC412 and 5-Azacytidine | NCT01202877 | Leukemia | 5-azacytidine PKC412 | 18 Years - | M.D. Anderson Cancer Center | |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | NCT01883362 | Acute Myeloid L... | Midostaurin Standard of Car... | 18 Years - 70 Years | Novartis | |
| A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | NCT00866281 | Acute Myeloid L... Acute Lymphobla... | midostaurin | 3 Months - 18 Years | Novartis | |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | NCT03379727 | Acute Myeloid L... | Midostaurin Cytarabine anthracycline (... | 18 Years - | Novartis | |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | NCT03591510 | FLT3-mutated Ac... | Midostaurin Fludarabine Cytarabine Daunorubicin or... Mitoxantrone Etoposide | 3 Months - 17 Years | Novartis | |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | NCT03512197 | Acute Myeloid L... | Midostaurin Placebo Chemotherapy | 18 Years - | Novartis | |
| A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | NCT02078609 | AML and High Ri... | LGH447 LGH447 + midost... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
